|
Dear VIJAY PITHADIA:
Your May 2013 digital issue of P&T journal is available.
This issue contains:
Feature articles
- FDA Strategies to Prevent and Respond to Drug Shortages
Finding a Better Way to Predict and Prevent Company Closures
To stave off a shortage of doxorubicin in 2011 and 2012, the FDA expedited the approval of a company's unapproved manufacturing process. Paying companies sufficiently so that they can invest in their facilities when needed is just one of many steps that could be taken to rectify future shortages.
- Biosimilars
Part 1: Proposed Regulatory Criteria for FDA Approval
Biosimilars, although not identical to their originator product, are expected to become essential in reducing health care costs and improving access to lifesaving drugs. The FDA must find a way to balance rigorous testing to ensure quality, as is done for generic chemical drugs, with providing a cost-efficient way to expedite approvals of these products.
- Comparison of Adverse Events and Hospital Length of Stay Associated With Various Amphotericin B Formulations
Sequential Conventional Amphotericin B/Lipid Versus Lipid-Only Therapy For the Treatment of Invasive Fungal Infections in Hospitalized Patients
Clinicians who prescribe amphotericin B should keep in mind the potential for nephrotoxicity. Lipid-based formulations can be less toxic than the conventional form but may also be more expensive. Patient outcomes and cost-effectiveness of the various formulations are discussed.
- MEETING HIGHLIGHTS
American Academy of Dermatology
Cardiovascular Research Technologies 2013
American College of Cardiology
Dermatology topics include agents for psoriasis, urticaria, and infantile hemangiomas. The pros and cons of antiplatelet drugs prasugrel (Effient) and ticagrelor (Brilinta) are discussed, and an investigational agent, cangrelor, shows promise in reducing ischemic events when compared with clopidogrel (Plavix).
Plus our regular columns: Medication Errors, Prescription: Washington, New Drugs/Drug News/New Medical Devices, and Pharmaceutical Approval Update.
Click here to begin reading the current issue.
Click here to subscribe to P&T journal
Call for Papers
P&T is accepting article submissions from its readers. We welcome a wide variety of manuscripts, including drug class reviews, disease state management reviews, pharmacoeconomic analyses, outcomes research evaluations, DUEs, P&T committee experiences, commentaries, book reviews, and letters to the editor. Please contact Sonja Sherritze, via phone (267-685-2779) or mobile 267-907-5642) or e-mail (ssherritze@medimedia.com) for more information.
We hope you enjoy this issue of P&T. If you have any comments or questions about this digital format, please send an e-mail to me at tberberabe@medimedia.com
Tony Berberabe, MPH
Senior Web Editor |
Posts
